Dec 03, 2020 / 07:40PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
Very welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team. Pleased to introduce from BioMarin, we have Hank Fuchs, President of Worldwide Research and Development; and Brian Mueller, Executive Vice President and Chief Financial Officer. So welcome, Brian, I think you have some interim remarks to make.
Brian R. Mueller - BioMarin Pharmaceutical Inc. - Executive VP & CFO
I do. Thank you, Josh, and thank you all for your interest in BioMarin. 2020 has been an eventful year for us. Developments this year have us set up for more significant updates in 2021. Our next potential product approval will be with vosoritide for the treatment of children with achondroplasia, which is the most common form of dwarfism. Marketing applications in both the United States and Europe are currently under review by health authorities, setting the stage for potential approvals in the second half of 2021.
Vosoritide represents a tremendous
Biomarin Pharmaceutical Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 04, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers